FDA rejects Rocket Pharma’s ultra-rare immune disease gene therapy over manufacturing

The FDA rejected Rocket Pharmaceuticals’ gene therapy for leukocyte adhesion deficiency-I (LAD-I), requesting “limited additional” manufacturing information.

The company announced the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Elucida Oncology nabs more funds for its take on ADCs, sees potential in radiotherapy partnership

Elucida Oncology has raised another approximately $30 million to bring its version of antibody-drug conjugates to more patients in the clinical setting, the company told

June 24, 2023

Introducing Pα+ – Psychedelic Alpha

I want to start by thanking you all for your ongoing readership. Every time I pen something and send it out into the ether I

November 3, 2023

TMF Stock Analysis and how I am playing the big economic data with TMF stock & TLT stock

August 30, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.